Official announcement! League Pharma's first class 1 anti-drug-resistant bacteria new drug Kantaiamine listing application accepted

Conteazole is a new type of antimicrobial antimicrobial spree with a new drug structure used to treat gerrane-positive bacteria, including infections caused by methicillin-resistant Staphylococcus aureus (MRSA)The first-ever drug of its kind, Linaeamine, was developed and marketed by Pfizer, with global sales peaking at more than $1.3 billionOn September 21, 2019, at the 4th China Pharmaceutical Innovation and Investment Conference, DrYuan Zhengyu, founder of Monco Pharmaceuticals, released the results of phase III clinical trials of Kantaiamine for complex skin and soft tissue infections for the first timeit is reported that this double-blind test is a "head-to-head" comparison study conducted by Conteamineand and the same drug Linaethamine, which enrolled a total of 719 patientsThe clinical results showed that the clinical cure rates of Conteazole and Linazole were 93.0% and 93.4%, respectively, in post-treatment visitsThe clinical efficacy of cantamine on gram-positive bacteria, including multi-drug-resistant MRSA infection, is shown to be comparable to that of the "heavy bomb" class antibacterial drug linazinethe overall incidence of adverse events (TEAE) after treatment in Phase III clinical trials, which were comparable in both the Conteamine and Linazole, and were mostly mild or moderateHowever, in hematological examinations associated with bone marrow inhibition, the incidence of adverse reactions in the Conteamine group was significantly lower than that of the linamine groupIn particular, in patients treated for more than 10 days, platelet counts decreased by more than 30% compared to baselines at the end of treatment, with 25.4% of linazine amine groups and only 2.5% of the Conteamine groupConteazole is also the world's first ketone, a major breakthrough in phase III clinical trials that has shown hematologic toxicity to be superior to linazinethe listing application for the first class 1 new drug, Kantaiamine, is based on the results of this excellent Phase III clinical trial and is expected to provide a new safe and effective drug option for patients with drug-resistant bacterial infections2016, 14 departments, including the National Health and Family Planning Commission and the Development and Reform Commission, jointly issued the National Action Plan for The Control of Bacterial Resistance (2016-2020), implementing comprehensive governance strategies and measures at the national level to address the risk challenges posed by bacterial resistanceThe first goal by 2020 is to develop 1-2 new antimicrobials to be marketedThe successful development of Kantaiamine will also represent China's antimicrobial new drug research and development capabilities to the forefront of the worldAbout Union Pharmaceuticals Co., Ltd A.C., a clinical-stage biotechnology company focused on the discovery, development and commercialization of antimicrobial drugs for multi-drug-resistant (MDR) "superbug" infections Since its establishment in 2007, a research pipeline has been established that includes Conteamine (MRX-I), Conteamine phosphate (MRX-4), MRX-8 (a new polymycoccal drug for MDR gram-negative bacteria), and MRX-12 (a new type of drug for MDR gram-negative bacteria) Both Conteamine and Conteazolamphosphate were recognized by the FDA for QIDP and rapid review The company has raised a total of $107m through leading wind investments, including Morningside Ventures, BVCF, GP Healthcare Capital, GP TMT Capital, 3E Bioventures Capital and Delian Capital For more information, please visit: